Clinical Trials Logo

Ketamine Adverse Reaction clinical trials

View clinical trials related to Ketamine Adverse Reaction.

Filter by:
  • None
  • Page 1

NCT ID: NCT04701008 Completed - Pain, Postoperative Clinical Trials

Efficacy of Ketamine in Post Anesthesia Recovery Room

Start date: September 1, 2020
Phase:
Study type: Observational

Observational study to assess efficacy of IV ketamine bolus when used in the post anesthesia recovery unit for uncontrolled pain despite use of opioids.

NCT ID: NCT04490031 Recruiting - Clinical trials for Ketamine Adverse Reaction

Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Start date: March 1, 2020
Phase: Phase 4
Study type: Interventional

This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.

NCT ID: NCT03979105 Completed - Pain Clinical Trials

Cardiovascular Safety After Continuous Ketamine Infusion

Start date: July 1, 2017
Phase:
Study type: Observational

Observational study that evaluate the cardiovascular and neuropsychiatric side effects of ketamine analgesic infusions for acute pain

NCT ID: NCT03525912 Completed - Pain, Postoperative Clinical Trials

Neuropsychiatric and Cardiovascular Side Effects in Ketamine Analgesic Infusions

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

Evaluation of neuropsychiatric and cardiovascular side effects of low dose ketamine analgesic infusion for postoperative pain

NCT ID: NCT03067974 Terminated - Clinical trials for Ketamine Adverse Reaction

Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study

Start date: September 21, 2017
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the feasibility of intranasal ketamine for adequate sedation of children undergoing minor procedures in the Emergency Department. An intranasal dose of 10mg/kg will be used in patients requiring procedural sedation. The investigators hypothesize that this dose of intranasal ketamine will be able to provide adequate sedation and analgesia for the physician to successfully complete the planned diagnostic or therapeutic intervention (Pediatr Emer Care 2012;28: 767-70). The primary endpoint will be successful sedation, as defined by the ability to complete the planned procedure without rescue medication, which includes re-dosing of the same medication.

NCT ID: NCT00486902 Completed - Clinical trials for Effects of; Anesthesia, Spinal and Epidural, in Pregnancy

Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?

Start date: July 2006
Phase: N/A
Study type: Interventional

Pain control after cesarean delivery is associated with improved breastfeeding and infant rooming-in times. In addition, inadequate analgesia leads to elevated plasma catecholamine concentrations, which negatively affect every organ system. There is growing evidence that ketamine, N-methyl-D-aspartate receptor antagonist, is efficacious when used as an adjuvant in postoperative pain control. A 2006 Cochrane Collaboration systemic review and meta-analysis concluded, "Ketamine in subanesthetic doses….is effective in reducing morphine requirements in the first 24 hours after surgery." Ketamine's prolonged analgesic effect, despite its short half-life and its use in low doses, is theorized to be due to blockade of spinal cord central sensitization. Central sensitization is a phenomenon whereby repeated painful stimulus leads to more severe pain perception over time despite no change in the intensity of the painful stimulus.Ketamine may also prevent the development of acute opioid tolerance. Ketamine's analgesic effects have also demonstrated in the obstetric population. Post-cesarean delivery morphine requirements in women who received ketamine as part of a general anesthesia technique were decreased. Similary, low-dose ketamine in conjunction with bupivacaine-only spinal anesthesia reduced postoperative analgesic requirements compared to bupivacaine-only spinal anesthesia and bupivacaine-fentanyl spinal anesthesia. In the United States, healthy women scheduled for elective cesarean delivery commonly receive spinal anesthesia with bupivacaine-fentanyl-morphine. To our knowledge, IV ketamine has not been studied as an adjuvant to this regimen in the analgesic management in post-cesarean delivery patients. Multimodal therapy for postoperative pain control is widely practiced due to the advantage it provides in blocking multiple pain pathways while minimizing side effects of each individual pain medication. We hypothesize that low dose intravenous ketamine will improve multi-modal post-cesarean analgesia compared to placebo. The purpose of this study is to evaluate this hypothesis and study the possible side effects of this regimen in combination with bupivacaine-fentanyl-morphine spinal anesthesia.